摘要
目的观察紫杉醇(PTX)联合奈达铂(NDP)治疗晚期非小细胞肺癌的疗效及不良反应。方法 48例晚期非小细胞肺癌患者应用紫杉醇(PTX)联合奈达铂(NDP)方案化疗:PTX 135~175 mg/m2,静脉滴注,第1天;NDP 80~100 mg/m2,静脉滴注,第2天,21 d为1个周期。结果全组48例患者中,完全缓解率(CR)3例(6.3%),部分缓解率(PR)16例(33.3%),稳定(SD)22例(45.8%),病情进展(PD)7例(14.6%)。有效率(RR)为39.6%,疾病控制率(DCR)为85.4%。主要不良反应为骨髓抑制及胃肠道反应,肝、肾毒性较轻。结论紫杉醇联合奈达铂治疗晚期非小细胞肺癌不良反应轻,疗效较好,值得临床推广。
Objective To evaluate the efficacy and side effects of combined chemotherapy with nedaplat plus paclitaxel in treatment of advanced non-small cell lung cancer. Methods Forty-eight patients with advanced non-samll cell lung cancer were treated with nedaplat plus paclitaxel.Paclitaxel was administered on days 1 at a dose of 135-175 mg/m2,nedaplat was administered on days 2 at a dose of 80-100 mg/m2,every 21 days was one cycle.Results Among the forty-eight patients,the response rates were 39.6%,disease control rate was 85.4%.Complete reponse rate was 6.3%,partial reponse rate was 33.3%,stable disease rate was 45.8%,progressive disease rate was 14.6%.The main side effects were neutropenia,thrombocytopenia,nausea and vomiting.There was no obvious side effect in liver or kidney.Conclusion Nedaplat combined paclitaxel were effective and has less side effect in the treatment of advanced non-small cell lung cancer,it deserves spreading and applying.
出处
《临床医学》
CAS
2011年第1期3-4,共2页
Clinical Medicine
关键词
紫杉醇
奈达铂
晚期非小细胞肺癌
Paclitaxel
Nedaplat
Advanced non-small cell lung cancer